RU2003131695A - Способ воздействия на нейродегенеративное нарушение или нарушение миелинизации - Google Patents
Способ воздействия на нейродегенеративное нарушение или нарушение миелинизации Download PDFInfo
- Publication number
- RU2003131695A RU2003131695A RU2003131695/14A RU2003131695A RU2003131695A RU 2003131695 A RU2003131695 A RU 2003131695A RU 2003131695/14 A RU2003131695/14 A RU 2003131695/14A RU 2003131695 A RU2003131695 A RU 2003131695A RU 2003131695 A RU2003131695 A RU 2003131695A
- Authority
- RU
- Russia
- Prior art keywords
- disorders
- polyneuropathy
- disturbance
- subject
- peripheral
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 9
- 230000000626 neurodegenerative effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 206010036105 Polyneuropathy Diseases 0.000 claims 3
- 230000007824 polyneuropathy Effects 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 230000007171 neuropathology Effects 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 206010010254 Concussion Diseases 0.000 claims 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 1
- 208000013875 Heart injury Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029174 Nerve compression Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000003710 cerebral cortex Anatomy 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000009514 concussion Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 210000000609 ganglia Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000005518 mononeuropathy Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000023105 myelination Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 210000000273 spinal nerve root Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 210000001103 thalamus Anatomy 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 102100036197 Prosaposin Human genes 0.000 abstract 2
- 101710152403 Prosaposin Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 208000004296 neuralgia Diseases 0.000 abstract 2
- 208000021722 neuropathic pain Diseases 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (6)
1. Способ воздействия на нейродегенеративные нарушения и нарушения миелинизации у субъекта путем введения субъекту нуждающемуся в этом эффективного количества пептида, содержащего аминокислотную последовательность Thr-R1-Lue-Ile-Asp-Asn-Asn-Ala-Thr-Glu-Glu-Ile-Leu-Tyr, где R1 является D-аланином (SEQ ID N:2).
2. Способ по п.1, в котором указанные нарушения выбирают из группы, содержащей: полиневропатию, мононевропатию, неврому, сдавливание нерва, травма нерва, контузия, опухоль или неполное пересечение спинного мозга, инфаркт или травму стволового мозга, таламуса или коры головного мозга, сдавливание, разрыв или воспаление дорсальных корней ганглиев, постполиосиндром, травматическое или ишемическое нарушение центральной или периферической нервной системы, рассеянный склероз.
3. Способ по п.2, в котором полиневропатия представляет собой диабетическую периферийную невропатологию.
4. Способ по п.2, в котором полиневропатия представляет собой периферийную невропатологию, приобретенную в результате хемиотерапии.
5. Способ по п.1, в котором указанными нарушениями являются ишемические нарушения в центральной или переферической нервной системе.
6. Способ по п.1, в котором указанный пептид находится в форме, приемлемой для введения путем, выбранным из группы, включающей: внутривенное, внутримышечное, внутрикожное, подкожное, интракраниальное, в цереброспинальную жидкость, местное, пероральное, чрезкожное трансмукозальное или интраназальное введение.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/611,307 US6271196B1 (en) | 1996-03-05 | 1996-03-05 | Methods of alleviating neuropathic pain using prosaposin-derived peptides |
| US08/611,307 | 1996-03-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU98118091/04A Division RU2223969C2 (ru) | 1996-03-05 | 1997-03-05 | Способы облегчения нейропатической боли с применением пептидов, являющихся производными просапозина |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003131695A true RU2003131695A (ru) | 2005-04-10 |
| RU2266129C2 RU2266129C2 (ru) | 2005-12-20 |
Family
ID=24448513
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU98118091/04A RU2223969C2 (ru) | 1996-03-05 | 1997-03-05 | Способы облегчения нейропатической боли с применением пептидов, являющихся производными просапозина |
| RU2003131695/14A RU2266129C2 (ru) | 1996-03-05 | 1997-03-05 | Способ воздействия на нейродегенеративное нарушение или нарушение миелинизации |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU98118091/04A RU2223969C2 (ru) | 1996-03-05 | 1997-03-05 | Способы облегчения нейропатической боли с применением пептидов, являющихся производными просапозина |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6271196B1 (ru) |
| EP (1) | EP0929569B1 (ru) |
| JP (1) | JP4138006B2 (ru) |
| KR (1) | KR100507715B1 (ru) |
| AT (1) | ATE340187T1 (ru) |
| AU (1) | AU734566B2 (ru) |
| CA (1) | CA2248139C (ru) |
| CZ (1) | CZ297384B6 (ru) |
| DE (1) | DE69736712T2 (ru) |
| IL (1) | IL126082A0 (ru) |
| NO (1) | NO984093L (ru) |
| NZ (1) | NZ331757A (ru) |
| PL (1) | PL187917B1 (ru) |
| RU (2) | RU2223969C2 (ru) |
| SK (1) | SK122898A3 (ru) |
| WO (1) | WO1997032895A1 (ru) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2317829C2 (ru) * | 2005-10-05 | 2008-02-27 | Федеральное государственное учреждение науки "Екатеринбургский медицинский научный центр профилактики и охраны здоровья рабочих промпредприятий" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека | Способ лечения мононевропатий верхних конечностей |
| RU2430162C2 (ru) * | 2005-05-13 | 2011-09-27 | Шарите Универзитетсмедицин-Берлин | Варианты эритропоэтина |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571787A (en) * | 1993-07-30 | 1996-11-05 | Myelos Corporation | Prosaposin as a neurotrophic factor |
| US6849602B1 (en) * | 1996-03-05 | 2005-02-01 | The Regents Of The University Of California | Compositions for alleviating neuropathic pain with prosaposin receptor agonists |
| EP0979238A4 (en) * | 1997-03-05 | 2000-08-23 | Univ California | METHOD FOR HEALING NEUROPATHIC PAIN |
| JP2001524944A (ja) * | 1997-03-05 | 2001-12-04 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 神経障害性疼痛の緩和方法 |
| AU7795698A (en) * | 1997-03-24 | 1998-10-20 | Myelos Corporation | Synthetic saposin c-derived neurotrophic peptides |
| AU9774698A (en) * | 1997-09-09 | 1999-03-29 | Regents Of The University Of California, The | Inhibition of apoptotis using prosaposin receptor agonists |
| US6458357B1 (en) * | 1997-09-09 | 2002-10-01 | Myelos Corporation | Retro-inverso neurotrophic and analgesic peptides |
| AU751034B2 (en) * | 1998-08-28 | 2002-08-08 | Myelos Corporation | Cyclic prosaposin-derived peptides and uses thereof |
| US20020028783A1 (en) * | 1999-09-09 | 2002-03-07 | O'brien John S. | Method of stimulating prosaposin receptor activity |
| USRE45976E1 (en) * | 1999-02-24 | 2016-04-19 | Tact Ip, Llc | Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally |
| IL145527A0 (en) * | 1999-03-30 | 2002-06-30 | Myelos Corp | Retro-inverso prosaposin-derived peptides and use thereof |
| US7309687B1 (en) | 1999-04-13 | 2007-12-18 | The Kenneth S. Warren Institute, Inc. | Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin |
| US7345019B1 (en) | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
| WO2000077028A1 (en) * | 1999-06-16 | 2000-12-21 | Myelos Corporation | Retro-inverso peptides derived from interleukin-3 |
| WO2000077029A1 (en) * | 1999-06-16 | 2000-12-21 | Myelos Corporation | Retro-inverso peptides derived from leukemia inhibitory factor |
| WO2000077033A1 (en) * | 1999-06-16 | 2000-12-21 | Myelos Corporation | Retro-inverso peptides derived from interleukin-6 |
| US7109168B1 (en) | 2000-06-16 | 2006-09-19 | Myelos Corporation | Retro-inverso peptides derived from leukemia inhibitory factor |
| US7135461B1 (en) | 2000-06-16 | 2006-11-14 | Myelos Corporation | Retro-inverso peptides derived from interleukin-6 |
| US20040170955A1 (en) * | 2000-09-08 | 2004-09-02 | Wadih Arap | Human and mouse targeting peptides identified by phage display |
| US20050074747A1 (en) * | 2000-09-08 | 2005-04-07 | Wadih Arap | Biopanning and rapid analysis of selective interactive ligands (brasil) |
| US7452964B2 (en) | 2001-09-07 | 2008-11-18 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides against placenta and adipose tissues |
| US7420030B2 (en) * | 2000-09-08 | 2008-09-02 | The Board Of Regents Of The University Of Texas System | Aminopeptidase A (APA) targeting peptides for the treatment of cancer |
| US6531121B2 (en) | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| US20060287240A1 (en) * | 2001-03-09 | 2006-12-21 | O'brien John S | Method of stimulating prosaposin receptor activity |
| US20040176290A1 (en) * | 2001-07-18 | 2004-09-09 | Renata Pasqualini | Anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration |
| US7671010B2 (en) * | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
| US8507445B2 (en) * | 2001-09-07 | 2013-08-13 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
| US20040048243A1 (en) * | 2001-09-07 | 2004-03-11 | Wadih Arap | Methods and compositions for in vitro targeting |
| US20040096089A1 (en) * | 2002-08-16 | 2004-05-20 | David Borsook | Non-invasive functional imaging of peripheral nervous system activation in humans and animals |
| US7166691B2 (en) * | 2002-12-20 | 2007-01-23 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Saposin C and receptors as targets for treatment of benign and malignant disorders |
| DK1605965T3 (da) * | 2003-03-26 | 2013-04-15 | Evotec Internat Gmbh | Anvendelse af saposin-beslægtede proteiner til forebyggelse og behandling af obesitet, diabetes og/eller metabolisk syndrom |
| JP2006521399A (ja) * | 2003-03-28 | 2006-09-21 | アカディア ファーマシューティカルズ，インコーポレーテッド | 疼痛管理用ムスカリンｍ１受容体アゴニスト |
| US7834147B2 (en) * | 2003-04-28 | 2010-11-16 | Childrens Hospital Medical Center | Saposin C-DOPS: a novel anti-tumor agent |
| CN100366286C (zh) * | 2003-04-28 | 2008-02-06 | 常州南云科技有限公司 | Saposin C-DOPS:一种抗癌新药 |
| US9345745B2 (en) * | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
| US7964585B2 (en) * | 2006-03-14 | 2011-06-21 | Case Western Reserve University | Composition and method of treating peripheral neuropathy |
| RU2345786C2 (ru) * | 2007-02-27 | 2009-02-10 | Андрей Евгеньевич Кульчиков | Способ лечения непрерывно-прогредиентных дегенеративных и демиелинизирующих заболеваний |
| SG10201604530SA (en) | 2008-01-22 | 2016-07-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| RU2561582C2 (ru) * | 2010-11-19 | 2015-08-27 | Российская Федерация в лице Министерства промышленности и торговли Российской Федерации | Инъекционная лекарственная форма олигопептидного препарата для лечения рассеянного склероза и способ ее получения |
| WO2012115185A1 (ja) * | 2011-02-23 | 2012-08-30 | 北海道公立大学法人札幌医科大学 | 疼痛を治療、改善、または予防するための組成物 |
| RU2669692C1 (ru) * | 2017-08-14 | 2018-10-15 | Павел Андреевич Канаев | Способ получения комплекса биологически активных пептидов обладающих нейротропной активностью |
| CN114642720A (zh) | 2018-03-23 | 2022-06-21 | 百祥制药公司 | 皂化蛋白c药物组合物和治疗癌症的方法 |
| EP3774848B1 (en) | 2018-03-29 | 2023-02-22 | Lateral Ip Pty Ltd | Cyclic peptides and uses thereof |
| US20240316146A1 (en) * | 2021-01-09 | 2024-09-26 | Bexion Pharmaceuticals Inc | Methods of reducing neuropathy and neuropathic symptoms and treating cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE108459T1 (de) | 1986-04-22 | 1994-07-15 | Salk Inst For Biological Studi | Antagonisten des fibroblasten-wachstumsfaktors. |
| DD298412A5 (de) * | 1989-04-28 | 1992-02-20 | ������@���Kk�� | Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele |
| US5169764A (en) * | 1990-08-08 | 1992-12-08 | Regeneron Pharmaceuticals, Inc. | Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras |
| US5187151A (en) * | 1991-02-12 | 1993-02-16 | Genentech, Inc. | Use of binding protein with igf-i as an anabolic growth promoting agent |
| RU2007417C1 (ru) * | 1991-06-21 | 1994-02-15 | Российский государственный медицинский университет | Способ получения плацентарного протеина |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| US5534495A (en) * | 1993-05-25 | 1996-07-09 | Advanced Peptides And Biotechnology Sciences | Treatment of non-HIV neuropathic pain syndromes |
| US5571787A (en) | 1993-07-30 | 1996-11-05 | Myelos Corporation | Prosaposin as a neurotrophic factor |
| US5700909A (en) * | 1993-07-30 | 1997-12-23 | The Regents Of The University Of California | Prosaposin and cytokine-derived peptides |
| JPH09509140A (ja) * | 1993-11-15 | 1997-09-16 | セルトリックス ファーマシューティカルズ，インコーポレイテッド | 神経学的障害の治療方法 |
| EP0979238A4 (en) * | 1997-03-05 | 2000-08-23 | Univ California | METHOD FOR HEALING NEUROPATHIC PAIN |
| AU7795698A (en) * | 1997-03-24 | 1998-10-20 | Myelos Corporation | Synthetic saposin c-derived neurotrophic peptides |
-
1996
- 1996-03-05 US US08/611,307 patent/US6271196B1/en not_active Expired - Fee Related
-
1997
- 1997-03-05 AT AT97916005T patent/ATE340187T1/de not_active IP Right Cessation
- 1997-03-05 KR KR1019980707151A patent/KR100507715B1/ko not_active Expired - Fee Related
- 1997-03-05 SK SK1228-98A patent/SK122898A3/sk unknown
- 1997-03-05 RU RU98118091/04A patent/RU2223969C2/ru not_active IP Right Cessation
- 1997-03-05 CZ CZ0283998A patent/CZ297384B6/cs not_active IP Right Cessation
- 1997-03-05 EP EP97916005A patent/EP0929569B1/en not_active Expired - Lifetime
- 1997-03-05 DE DE69736712T patent/DE69736712T2/de not_active Expired - Fee Related
- 1997-03-05 IL IL12608297A patent/IL126082A0/xx unknown
- 1997-03-05 NZ NZ331757A patent/NZ331757A/en active IP Right Revival
- 1997-03-05 WO PCT/US1997/004143 patent/WO1997032895A1/en not_active Ceased
- 1997-03-05 JP JP53205097A patent/JP4138006B2/ja not_active Expired - Fee Related
- 1997-03-05 CA CA002248139A patent/CA2248139C/en not_active Expired - Fee Related
- 1997-03-05 AU AU23286/97A patent/AU734566B2/en not_active Ceased
- 1997-03-05 RU RU2003131695/14A patent/RU2266129C2/ru not_active IP Right Cessation
- 1997-03-05 PL PL32870197A patent/PL187917B1/pl not_active IP Right Cessation
-
1998
- 1998-09-04 NO NO984093A patent/NO984093L/no not_active Application Discontinuation
-
1999
- 1999-01-15 US US09/231,159 patent/US6268347B1/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2430162C2 (ru) * | 2005-05-13 | 2011-09-27 | Шарите Универзитетсмедицин-Берлин | Варианты эритропоэтина |
| RU2317829C2 (ru) * | 2005-10-05 | 2008-02-27 | Федеральное государственное учреждение науки "Екатеринбургский медицинский научный центр профилактики и охраны здоровья рабочих промпредприятий" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека | Способ лечения мононевропатий верхних конечностей |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69736712D1 (de) | 2006-11-02 |
| NO984093D0 (no) | 1998-09-04 |
| ATE340187T1 (de) | 2006-10-15 |
| NO984093L (no) | 1998-11-04 |
| KR100507715B1 (ko) | 2006-05-26 |
| AU734566B2 (en) | 2001-06-14 |
| SK122898A3 (en) | 2000-02-14 |
| PL328701A1 (en) | 1999-02-15 |
| US6271196B1 (en) | 2001-08-07 |
| WO1997032895A1 (en) | 1997-09-12 |
| NZ331757A (en) | 1999-10-28 |
| US6268347B1 (en) | 2001-07-31 |
| EP0929569A4 (en) | 2000-08-23 |
| DE69736712T2 (de) | 2007-09-13 |
| CA2248139C (en) | 2004-05-18 |
| PL187917B1 (pl) | 2004-11-30 |
| CA2248139A1 (en) | 1997-09-12 |
| JP4138006B2 (ja) | 2008-08-20 |
| CZ297384B6 (cs) | 2006-11-15 |
| IL126082A0 (en) | 1999-05-09 |
| EP0929569A1 (en) | 1999-07-21 |
| RU2266129C2 (ru) | 2005-12-20 |
| AU2328697A (en) | 1997-09-22 |
| KR19990087686A (ko) | 1999-12-27 |
| EP0929569B1 (en) | 2006-09-20 |
| CZ283998A3 (cs) | 1999-05-12 |
| RU2223969C2 (ru) | 2004-02-20 |
| JP2000506853A (ja) | 2000-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003131695A (ru) | Способ воздействия на нейродегенеративное нарушение или нарушение миелинизации | |
| Wada et al. | Persistent seizure susceptibility and recurrent spontaneous seizures in kindled cats | |
| Kuperman | Effects of acrylamide on the central nervous system of the cat | |
| EP4487916A3 (en) | Ion channel modulators | |
| EP0647137A4 (en) | GLYCINE RECEPTOR ANTAGONISTS AND THEIR USE. | |
| Hernandez-Peon et al. | An experimental study of the anticonvulsive and relaxant actions of Valium | |
| MX9604985A (es) | Cardiotropina y usos de la misma. | |
| Gros et al. | Long term results of stereotaxic surgery for infantile dystonia and dyskinesia | |
| Eriksson et al. | Pain relief from peripheral conditioning stimulation in patients with chronic facial pain | |
| Gage et al. | Local regulation of compensatory noradrenergic hyperactivity in the partially denervated hippocampus | |
| Marrosu et al. | Localized epileptiform activity induced by murine CRF in rats | |
| Hinsey et al. | Sensory components of the phrenic nerve of the cat | |
| Bimpong-Buta et al. | Carbamazepine-induced choreoathetoid dyskinesias | |
| WO1993000427A3 (en) | Neurite growth regulatory factors | |
| Fiol et al. | Methohexital (Brevital) effect on electrocorticogram may be misleading | |
| WO2002005798A3 (en) | Pharmaceutical compositions for treating neurological disorders | |
| Ehle | Effects of phenytoin on amygdaloid kindled seizures in the rat | |
| Czuczwar et al. | Effects of some antiepileptic drugs in pentetrazol‐induced convulsions in mice lesioned with kainic acid | |
| Doherty et al. | Experimental louping-ill in sheep and lambs: II. Neuropathology | |
| Escandon et al. | Developmental expression of the chicken nerve growth factor receptor gene during brain morphogenesis | |
| CA2274985A1 (en) | Synthetic antisense oligodeoxynucleotides targeted to human acetylcholinesterase | |
| DE60141759D1 (de) | Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf | |
| WO2017052160A1 (ko) | 통증 치료용 조성물 | |
| Grahnstedt et al. | Awakening thresholds for electrical brain stimulation in five sleep-waking stages in the cat | |
| Fox et al. | Changes in F wave size during dentatotomy. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20080306 |